We also observed a significant decrease in lung colony counts in animals on 7th and 14th day of Rutin infection after treatment. SCD-1 was observed to control fungemia in other organs also. The fungal infection was cleared by day from liver of the animals in most of the treated groups. Also, the pathogen was cleared from the spleen of animals belonging to all groups, with or without antifungal treatment. Sionov et al determined the efficacy of combination therapy using SB225002 Amphotericin B intralipid mixture and caspofungin in mice infected with A. fumigatus by intravenous route. The authors reported complete removal of pathogen from spleen and kidney of animals belonging to treatment groups on 14th day. A significant decrease in the level of serum biochemical parameters after treatment with SCD-1, in infected animals, suggested protective effect of compound on vital organs. Wallace et al determined the in vivo antifungal efficacy of liposomal nystatin in a neutropenic model of disseminated aspergillosis and observed no significant difference in the level of BUN and creatinine on day 5 or 19 as compared to their pre-dose level. The histopathological observations also showed that there was no or minimal inflammation and necrosis in lungs, liver and kidney of the animals treated with SCD-1, indicating its effectiveness in protecting the important organs of the body. In conclusion, present study was focused on in vivo safety and antifungal efficacy evaluation of a synthetic coumarin, SCD-1. It was found to be highly safe to the experimental animals, upto a dose of 300 mg/kg bw. The SCD-1 had protective effect against A. fumigatus infection as the treatment resulted in increased survival and effective pathogen clearance from organs by reducing the fungemia in animals. The most important aspect was the manifold safety of SCD-1 as demonstrated by its high LD50 cut-off value. In this study, we have tested three different doses of SCD-1 by different routes but much higher doses of SCD-1 can be administered safely owing to its high tolerable dose, thereby, resulting in an improved therapeutic profile.